Four molecular hallmarks — mitochondrial dysfunction, loss of proteostasis, cellular senescence, and epigenetic drift — converge into an interactive, self-reinforcing network underlying age-related macular degeneration, glaucoma, and diabetic retinopathy. Crucially, these hallmarks don't operate independently: in the retinal pigment epithelium's high-energy environment, mitochondrial dysfunction dominates AMD pathogenesis; in the mechanically stressed trabecular meshwork, senescence and epigenetic drift drive glaucoma; in the neurovascular unit, hyperglycemia creates a metabolic-epigenetic amplification loop sustaining diabetic retinopathy. Key intervention nodes identified include NLRP3 inflammasome activation, p62-mediated proteostasis, and NAD⁺ metabolism.
The conceptual contribution here is meaningful: framing divergent ocular pathologies as tissue-context-dependent outputs of a shared aging network reframes therapeutic strategy entirely. Rather than treating AMD, glaucoma, and diabetic retinopathy as separate diseases requiring separate drugs, a geroscience approach targeting upstream nodes like NAD⁺ metabolism or NLRP3 could theoretically address all three simultaneously. This aligns with accelerating interest in senolytics and partial epigenetic reprogramming — interventions showing early promise in animal models of retinal aging. That said, this is a review synthesis, not primary data, so the mechanistic framework remains largely inferential pending clinical validation. The identification of p62 and NLRP3 as shared nodes is actionable for drug development, but translating multi-target combination strategies from bench to ophthalmology clinics faces formidable pharmacokinetic and safety hurdles. Incremental in framing, but genuinely useful as a systems-level roadmap for investigators designing next-generation ocular therapeutics.
